BioCryst Pharmaceuticals reported $13.74M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
Chugai Pharma JPY 290.81B 26.77B Sep/2026
Daiichi Sankyo JPY 733.05B 40.68B Jun/2026
Gilead Sciences USD 1.9B 57M Sep/2026
GlaxoSmithKline GBP 6.28B 125M Jun/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Novavax USD 18.5M 8.49M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026